This study aimed to develop a multiparametric flow cytometry-based minimal residual disease (MRD) assessment protocol using the DURAClone method for patients with multiple myeloma (MM), particularly after autologous stem cell transplantation (ASCT).

Read More> https://multiplemyeloma.pocn.com/patient-management/multiparametric-flow-cytometry-based-mrd-assessment-with-duraclone-for-multiple-myeloma-post-asct/